IDEAYA Biosciences, Inc. (BST:30J)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.14B +32.3% |
| Revenue (ttm) | 195.38M +3,118.1% |
| Net Income | -121.47M |
| EPS | -1.37 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 24.19 |
| Previous Close | 24.23 |
| Day's Range | 24.04 - 25.17 |
| 52-Week Range | 18.30 - 32.60 |
| Beta | n/a |
| RSI | 40.73 |
| Earnings Date | Aug 5, 2026 |
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial numbers in USD Financial StatementsNews
IDEAYA Biosciences Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Positive clinical results for darovasertib in uveal melanoma support expedited NDA filing, with detailed efficacy and safety data to be presented at ASCO. Pipeline progress includes upcoming DLL3 ADC data, expansion into adjuvant/neoadjuvant settings, and strategic focus on PRMT5, MAT2A, and KAT6/7 programs.
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDEAYA Biosciences NASDAQ: IDYA said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlig...
IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Focused on clinical distinction and procedural innovation, the company targets high-growth lateral surgery and imaging markets, achieving positive EBITDA and strong cash flow. Recent launches in robotics and international expansion support continued outsized growth and profitability.
Ideaya Biosciences price target lowered to $50 from $52 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $50 from $52 and keeps an Outperform rating on the shares.
IDEAYA Biosciences Slides: Corporate presentation
IDEAYA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)
Reports Q1 revenue $6.56M, consensus $5.04M. “This was a transformational quarter for IDEAYA, with positive topline results from the OptimUM-02 registrational trial in first line HLA*A2-negative metas...
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR su...
IDEAYA Biosciences Earnings release: Q1 2026
IDEAYA Biosciences released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IDEAYA Biosciences Quarterly report: Q1 2026
IDEAYA Biosciences has published its Q1 2026 quarterly earnings report on May 5, 2026.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeut...
IDEAYA Biosciences Proxy statement: Proxy filing
IDEAYA Biosciences filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA
Ideaya Biosciences (IDYA) announced that the FDA has agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first line HLA A2-negative metastatic u...
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and will be presented in a late-breaking oral presentation at ASCO 2026 IDEAYA to initiate the RTOR sub...
IDEAYA Biosciences Proxy statement: Proxy filing
IDEAYA Biosciences filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-b...
Ideaya Biosciences price target raised to $58 from $52 at Wedbush
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $58 from $52 and keeps an Outperform rating on the shares. The firm notes the company reported topline data…
Ideaya Biosciences price target raised to $54 from $50 at Guggenheim
Guggenheim analyst Paul Jeng raised the firm’s price target on Ideaya Biosciences (IDYA) to $54 from $50 and keeps a Buy rating on the shares following positive topline results from…
Ideaya Biosciences price target raised to $53 from $49 at RBC Capital
RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $53 from $49 and keeps an Outperform rating on the shares. The firm is positive on the meaningfulness…
Ideaya Biosciences price target raised to $65 from $60 at Truist
Truist raised the firm’s price target on Ideaya Biosciences (IDYA) to $65 from $60 and keeps a Buy rating on the shares following topline results from Phase 2/3 registrational trial,…
Ideaya Biosciences rises 22.8%
Ideaya Biosciences (IDYA) is up 22.8%, or $6.96 to $37.46.
IDEAYA Biosciences Transcript: Study result
Darovasertib plus crizotinib significantly improved progression-free survival and response rates in HLA-A2 negative metastatic uveal melanoma, with a favorable safety profile and early signs of overall survival benefit. The combination is poised to become a new standard, with ongoing studies in broader patient populations and earlier disease settings.
IDEAYA Biosciences Press release: Study result
IDEAYA Biosciences issued a press release on April 13, 2026, disclosing material business information to investors.
IDEAYA Biosciences Slides: Study result
IDEAYA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial
Ideaya Biosciences (IDYA) and Servier announced topline results from their Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-lin...